Maxalt Paragraph IV Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
The first ANDA with a Paragraph IV certification for Merck's migraine therapy Maxalt was filed Sept. 2, according to FDA's Nov. 3 updated list of Paragraph IV filings